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Abstract
Current histopathologic classification schemes for gastric adenocarcinoma have limited clinical 
utility and are difficult to apply due to tumor heterogeneity. Elucidation of molecular subtypes of 
gastric cancer may contribute to our understanding of gastric cancer biology and to the 
development of new molecular markers that may lead to improved diagnosis, therapy, or 
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prognosis. We previously demonstrated that Epstein-Barr virus infected gastric cancers have a 
distinct human gene expression profile compared to uninfected cancers. We now examine the 
histopathologic features characterizing infected (n=14) and uninfected (n=89) cancers, the latter of 
which are now further divided into two major molecular subtypes based on expression patterns of 
93 RNAs. One uninfected gastric cancer subtype was distinguished by upregulation of three genes 
with neuroendocrine function (CHGA, GAST, and REG4 encoding chromogranin, gastrin and the 
secreted peptide REG4 involved in epithelial cell regeneration), implicating hormonal factors in 
the pathogenesis of a major class of gastric adenocarcinomas. Evidence of neuroendocrine 
differentiation (molecular, immunohistochemical, or morphologic) was mutually exclusive of 
EBV infection. EBV infected tumors tended to have solid-type morphology with lymphoid 
stroma. This study reveals novel molecular subtypes of gastric cancer and their associated 
morphologies that demonstrate divergent neuroendocrine features.
Background
Gastric adenocarcinoma has remarkable morphologically heterogeneity, and many 
descriptive histologic classification schemes have been proposed over the past several 
decades1,2,3,4,5,6. Although some histologic types have prognostic and epidemiologic 
correlates, further progress is needed to classify tumors in a manner that impacts patient 
management. Variable clinical behavior and response to intervention attest to underlying 
biologic diversity. The lack of strong predictors of clinical outcome with any single 
histologic classification scheme highlights the complicated landscape of gastric cancer 
morphology which hampers comparative analysis across studies and underscores the need to 
devise novel methods of predicting response to current and future therapies.
The widely used Lauren classification divides the majority of gastric cancers into intestinal 
and diffuse types, and this dichotomous scheme has some clinicopathologic and 
epidemiologic relevance. However, there are other histologic patterns of prognostic 
significance, such as mixed7,8,9,10, solid7,8,11,12, and hepatoid13,14, that are not distinguished 
under the Lauren scheme. Intratumoral heterogeneity is common, and different histologic 
features often coexist within a single tumor, thus confounding the morphologic classification 
attempts and raising concerns about their accuracy and reproducibility7,15,16,17.
Gastric adenocarcinomas also have diverse pathogenesis, with Helicobacter pylori and 
Epstein-Barr virus (EBV) both designated as associated class 1 oncogenic pathogens by the 
World Health Organization (WHO). Approximately 10% of gastric adenocarcinomas harbor 
EBV infection in the neoplastic epithelial cells18. The prevalence of EBV infection is 
significantly higher (>80%) in the specific histologic type variably termed “gastric 
carcinoma with lymphoid stroma” or “lymphoepithelioma-like carcinoma”19,20,21,22,23,24. 
This tumor type is characterized by undifferentiated epithelial cells and an abundant 
lymphocytic infiltrate distributed uniformly throughout the tumor, similar to EBV-
associated nasopharyngeal carcinoma. Gastric carcinoma with lymphoid stroma has a 
survival advantage over other histologic types22,23, however the literature varies on whether 
EBV positivity alone or histopathologic appearance trumps in assigning 
prognosis 23,25,26,27,28. When EBV-associated gastric cancers are classified according to 
their histologic patterns, some studies report predominance of Lauren intestinal type26, 
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tubular type26,29,30, Lauren diffuse type20,23,27, and medullary/solid type30,31. This 
variability may illustrate the interpretative bias inherent in applying morphologic criteria.
High grade neuroendocrine carcinoma is another heterogeneous group of gastric 
malignancies classified and staged separately from gastric adenocarcinomas by the WHO32. 
It is frequently under-recognized because of the broad morphologic spectrum (from classic 
small cell carcinoma to poorly defined large cell carcinoma) and overlap with poorly 
differentiated adenocarcinoma33,34,35,36. Admixed adenocarcinoma components can be 
found in tumors of any of the neuroendocrine carcinoma subtypes, presenting a challenge in 
terms of the overall tumor classification. In fact, evidence of focal neuroendocrine 
differentiation has been found in over 50% of tumors otherwise classified as 
adenocarcinoma37,38,39,40. It is particularly common in signet ring cell carcinomas, leading 
some to propose that signet ring cells derive from a pluripotent neuroendocrine stem 
cell 41,42,43,44. Molecular and infectious correlates of neuroendocrine differentiation have 
not been systematically investigated.
Molecular profiling holds promise for adding value in categorizing disease in a manner that 
is clinically meaningful. We previously demonstrated that EBV-infected gastric cancers 
have a distinct human gene expression profile compared to uninfected gastric cancers45. In 
the current study, we examine RNA expression patterns to further divide uninfected cancers 
into two principal molecular subtypes, and we evaluate associations with tumor histology 
and neuroendocrine gene expression. This study is the first, to our knowledge, to investigate 
the relationship between EBV infection and neuroendocrine differentiation in gastric cancer.
Materials and Methods
Tissue and molecular profiling
Consecutive gastric adenocarcinoma cases on which sufficient residual formalin-fixed 
paraffin-embedded tissue was available were assembled from pathology archives of three 
hospitals in disparate parts of the world, 30 from the University of North Carolina Hospitals 
in Chapel Hill, USA, 133 from Western Regional Hospital in Santa de Rosa, Honduras, and 
24 from Wakayama Medical University, Wakayama, Japan. RNA profile data on this case 
cohort were previously published, and histopathology correlates are the subject of the 
current study. Studies were performed with approval of the University of North Carolina 
Biomedical Institutional Review board45.
Paraffin-embedded tissue sections were stained with hematoxylin and eosin (H&E) and 
reviewed to identify tumor for subsequent macrodissection from unstained adjacent sections. 
Nucleic acid was extracted and RNA expression analysis was performed on the nCounter 
system (Nanostring) as previously described45. A custom panel of 96 RNAs (Gastrogenus 
v1™ panel) was measured which includes 73 human mRNAs of which 4 were housekeeper 
transcripts, 20 viral RNAs (7 latent and 9 lytic EBV mRNA transcripts, EBER1 and EBER2 
non-coding RNAs, and two cytomegalovirus mRNAs), and 3 spiked ERCC RNA controls. 
The human RNAs were selected based on their proposed roles in gastric cancer 
pathogenesis, inflammatory response, and/or gastric cancer therapeutic targeting and 
monitoring. The viral RNAs were selected to detect EBV and to measure expression of 
Speck et al. Page 3













latent and lytic viral transcripts. After excluding samples with insufficient RNA or 
insufficient histopathologic material for morphologic assessment, a total 103 gastric 
carcinomas were included in the study. Of note, biopsies tended to yield better quality RNA 
than did resection specimens, possibly because biopsies tend to be immersed in formalin 
preservative much more quickly than are resected tumors.
Histologic analysis
All tumors were classified by both the Lauren system1 and by the Carneiro system7,46. In the 
Carneiro classification of gastric cancer, mixed carcinomas consisting of both glands and 
infiltrating single cells, as well as solid carcinomas, are classified separately from purely 
gland-forming tumors and isolated-cell tumors. The latter two tumor categories correspond 
to Lauren intestinal and diffuse types, respectively. Solid carcinomas are composed of tumor 
cell sheets with little or no gland formation and these tend to form expansile rather than 
infiltrative masses11. Solid tumors typically lack a significant stromal component and 
correspond to the medullary type distinguished by Kubo4. Others have used yet another 
term, “cohesive carcinoma”8, when individual cells or small groups of tumor cells in solid/
medullary/cohesive formations lack investment by stroma in contrast to isolated-cell type. 
Thus, in the Carneiro classification scheme histologic group 1 is isolated-cell, group 2 is 
gland-forming, group 3 has mixed gland-forming and single cell components, and group 4 is 
solid. A number of cases remained unclassified by this four-group system due to the scant 
nature and quality of biopsy material. Tumors with neuroendocrine morphology by H&E 
were also placed in the unclassified category as well as being considered separately for 
statistical analysis (see below).
Morphologic features suggesting neuroendocrine differentiation on H&E were evaluated as 
previously described for neuroendocrine carcinomas, namely, nested/organoid, trabecular, 
and rosette-forming architecture, relative cellular monotony, eosinophilic cytoplasm, 
indistinct cellular borders, and evenly dispersed chromatin3,33,34,47. Formal mitotic counts 
were not performed due to a preponderance of small biopsy specimens with limited numbers 
of high-power fields; however, mitoses were noted in the majority of tumors with 
neuroendocrine features. Tumors were characterized as signet ring cell carcinomas if >50% 
of malignant cells were signet ring cells. The degree of chronic inflammatory cell infiltrate 
within the tumor was graded semi-quantitatively as mild, moderate, or severe. Stromal 
fibrosis (desmoplasia) was also graded semi-quantitatively as mild, moderate or severe, 
reflecting a relative proportion of stromal spindle cells to tumor cells.
Histochemistry
EBV encoded RNA (EBER) in situ hybridization was performed on paraffin sections (Leica 
BOND Max system with EBER ASR probe and oligo dT control probe detected using the 
Bond Polymer AP Red Detection reagents, Leica Microsystems Inc., Buffalo Grove, IL)48,49 
to determine if EBV was localized to malignant epithelial cells. EBV localization to 
scattered lymphocytes was seen in some EBV-positive and EBV-negative tumor tissues as 
previously reported50. Representative histologic tumor types from all three molecular groups 
were selected for immunohistochemistry using antibodies to chromogranin A (Leica, 1:200) 
and synaptophysin (Leica, 1:200). Avidin-biotin complex peroxidase techniques were used 
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for signal detection on 4 μm sections of formalin-fixed, paraffin-embedded tissues. Antigen 
retrieval in hot citrate buffer at pH 6.0 was applied before immunostaining.
Statistics
Unsupervised hierarchical clustering revealed the EBV-infected molecular subtype for 
which EBV localization to malignant cells was proven by EBER in situ hybridization. Two 
additional uninfected molecular classes of gastric cancer were identified on heat maps 
created using Cluster 3.0 and JavaTreeView software algorithms applied to log2 
transformed gene expression data collected on the nCounter system. Genes differentially 
expressed among the three molecular types of cancer were identified using non parametric 
Mann-Whitney tests, and p-values were adjusted using Bonferroni correction to account for 
multiple comparisons. A Bonferroni adjusted p value <0.05 connoted significant differential 
expression. Box plots show the median and middle two quartiles surrounded by whiskers 
depicting outliers which are far above or below the interquartile range (IQR) by 
>Q3+1.5*IQR or <Q1-1.5*IQR, respectively. Associations between discrete histologic 
parameters and the three molecular types of cancer were evaluated by Fisher's Exact Test or 
Pearson's Chi-squared test. Statistical analysis was repeated after limiting the cohort to the 
two uninfected gastric cancer molecular types.
Results
RNA expression profiling reveals three molecular subtypes of gastric adenocarcinoma
The 96-RNA probe test panel that included 73 human mRNAs, 20 viral RNAs, and three 
controls (Gastrogenus v1™ panel) was applied to 103 macrodissected gastric 
adenocarcinoma tissues. After data normalization, unsupervised clustering identified three 
major molecular subtypes, one with high expression of EBV RNAs, and two lacking 
substantial levels of EBV RNA. The cancers overexpressing EBV RNAs were called the 
EBV-positive molecular type (n=14), and all 14 were proven to have EBV localized to 
malignant cells by EBER in situ hybridization which is the gold standard assay for defining a 
tumor as infected 45,50. Three RNAs involved in the differentiation and signaling of 
neuroendocrine cells of the gut, CHGA (chromogranin), GAST (gastrin), and REG4 
(regenerating islet-derived family, member 4), were significantly overexpressed in one non-
infected molecular subtype. Henceforth, the two uninfected molecular subtypes are referred 
to as Neuroendocrine-high (NE-high, n=34) and Neuroendocrine-low (NE-low, n=55) (Fig 
1, Fig S1, Supplemental Digital Content 1, http://links.lww.com/AIMM/A57 ).
Neuroendocrine RNAs distinguish the three molecular subtypes
Of the 73 human RNAs that were measured, 43 were significantly differentially expressed 
among the three molecular groups. The 9 human genes more highly expressed in EBV-
positive compared with EBV-negative cancers are involved primarily in the anti-viral 
inflammatory/immune response as previously described45. The neuroendocrine markers 
CHGA, GAST, and REG4 were expressed at a lower level in the EBV-positive compared to 
the NE-high molecular type. Levels of these neuroendocrine markers in the NE-low 
molecular type were intermediate between those in the EBV-positive and NE-high groups, 
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suggesting that the EBV-positive tumors had the least amount neuroendocrine 
differentiation (Fig 1).
Statistical analysis comparing the NE-high and NE-low molecular types revealed differential 
expression of 32 RNAs (Table 1). Only three genes were upregulated in NE-high compared 
with the NE-low molecular subtype, and these were the three neuroendocrine markers. The 
remaining 29 RNAs were downregulated in the NE-high group, and these downregulated 
RNAs include adhesion factors and intracellular signaling molecules (ICAM1, FSCN1, 
SULF1, SPP1, INHBA), and collagen components COL1A1, COL1A2, and COL3A1. 
Additionally, many inflammatory and immune response genes are downregulated in the NE-
high compared to the NE-low molecular types, implicating stromal cells as a factor 
influencing clustering. The EBV genes EBER1, EBER2, and BLLF1 were relatively 
underexpressed in NE-high compared to the NE-low molecular types, although the levels of 
these viral RNAs did not approach the elevated levels seen in the EBV-infected carcinomas. 
Rare EBV-infected stromal lymphocytes could be a source of these viral RNAs in 
uninfected cancer tissues.
Histologic analysis
H&E stained sections were analyzed to determine histologic classification, to examine 
stromal content for the extent of chronic inflammation and fibrosis, and to query for 
morphologic evidence of neuroendocrine differentiation (Table 2). EBV-positive molecular 
type cancers were noted to have more chronic inflammation compared to NE-high or NE-
low tumors and were much more likely to be designated as “gastric carcinoma with 
lymphoid stroma” (Fig 2). 7/14 EBV-positive cancers received this designation versus 0/34 
NE-high and 1/55 NE-low cancers. Tumors with more lymphocytic infiltrate generally 
showed less stromal desmoplasia, and no EBV-positive molecular type cancers were noted 
to have severe stromal fibrosis. EBV-positive molecular type cancers were comprised of 
sheets or large nests of tumor cells with absent or minimal desmoplastic stroma, 
characteristic of solid carcinoma of the stomach. Focal gland formation was present in some 
of the otherwise solid-appearing EBV-positive cancers but the focal glands were not 
associated with stromal infiltration.
There was a statistically significant association between the four histologic Carneiro groups 
among the three molecular types (p<0.05) (Table 2, Fig 3). As described above, EBV-
positive carcinomas were predominantly group 4 solid. The NE-high molecular type had a 
greater proportion of group 1 isolated-cell histology (14/34 cases, 41%) compared to the 
EBV-positive (0/14) and NE-low type (10/55, 18%), and a greater proportion of signet ring 
cell carcinomas—11/34 (32%) NE-high tumors were signet ring cell carcinomas compared 
to 0/14 EBV-positive tumors and 4/55 (7%) NE-low tumors. Classification of tumors into 
Lauren categories did not have a statistically significant association with molecular 
subtypes.
Although all gastric cancers in this study were diagnosed as adenocarcinoma rather than 
neuroendocrine carcinoma, a number of cases were found to have architectural and cytologic 
neuroendocrine features on H&E stain, such as nested or rosette-forming architecture, 
cellular monotony, and evenly dispersed chromatin (Fig 4). In addition, some cases had 
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high-grade neuroendocrine features with increased nuclear/cytoplasmic ratios, 
hyperchromatic nuclei, and conspicuous mitotic activity. Four biopsy cases additionally 
showed extensive nuclear molding, single cell apoptosis, and crush artifact, fulfilling the 
criteria for classic small cell carcinoma (Fig 4E). Two of these small cell carcinoma cases 
were NE-high and two were NE-low molecular subtype. However, in other cases 
determination of high-grade vs. low-grade neuroendocrine tumor features could not be made 
due to the limited size of biopsy material. All tumors with any morphologic neuroendocrine 
features were separated out for purposes of statistical analysis. While none of the 14 EBV-
positive cancers had neuroendocrine features by H&E, such features were found in 4/34 NE-
high and 10/55 NE-low molecular type tumors, but this relationship did not reach statistical 
significance.
Genes associated with histologic subtypes
RNAs differentially expressed among the four Carneiro histologic groups included primarily 
viral RNAs and those human RNAs involved in the inflammatory/immune response. These 
RNAs were upregulated in group 4 solid carcinomas which includes the majority of EBV-
positive molecular type cancers. Four human RNAs not generally considered part of the 
inflammatory repertoire that were significantly differentially expressed among the histologic 
groups are CHGA (p=0.007), PLUNC (p=0.008), CYP2W1 (p=0.014), and PPARG 
(p=0.035). CHGA was expressed at a higher level in group 1 isolated-cell tumors and group 
3 mixed tumors, while PLUNC was expressed at higher level in group 4 solid tumors (Fig 
5). No RNAs were differentially expressed in association with morphological evidence of 
neuroendocrine differentiation. Similarly, no RNAs were significantly associated with the 
Lauren classification or with signet ring cell morphology.
Chromogranin RNA level and protein immunohistochemistry
Given the significant association of the molecular groups with the expression of 
neuroendocrine RNAs, we assessed neuroendocrine differentiation by 
immunohistochemistry for chromogranin and synaptophysin in representative tumors from 
the three molecular types (Table S1, Supplemental Digital Content 2, http://links.lww.com/
AIMM/A58 ). Immunohistochemistry could be performed only on a small fraction of study 
samples in part because tissue from many biopsy cases had been exhausted for RNA 
extraction. Immunohistochemistry was attempted in 16 cases with 14 yielding sufficient 
tissue for analysis, 5 NE-high cases, 7 NE-low cases, and 2 EBV-positive cases. In the NE-
high subtype, chromogranin staining was positive in 4/5 cases (1 NE/small cell carcinoma, 2 
isolated-cell carcinomas, and one mixed carcinoma). One NE-high case with neuroendocrine 
morphology was negative for chromogranin but positive for synaptophysin. In the NE-low 
subtype, chromogranin staining was positive in 1/7 cases (1 isolated-cell carcinoma) while 
negative in 2 solid carcinomas and 4 NE carcinomas, including two small cell carcinomas. 
Three of the four chromogranin-negative NE carcinomas were synaptophysin positive. 
Neither of the two EBV-positive cases had positive chromogranin or synaptophysin staining. 
No statistically significant correlation between chromogranin RNA level and protein 
expression could be established (p=0.06).
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Neuroendocrine differentiation is observed only in the non-EBV-infected molecular type 
cancers
Although only a small number of samples were investigated by immunohistochemistry, 
positive antibody staining for neuroendocrine markers was observed only in non-EBV-
infected molecular type cancers. EBV-positive molecular type cancer with solid morphology 
lacks chromogranin or synaptophysin-expressing malignant cells (Fig 6A-C). In contrast, 
scattered single tumor cells positive for chromogranin or synaptophysin were seen in NE-
high molecular type cancers that were group 1 isolated-cell histology (Fig 6D-F). NE-high 
tumors with signet ring cells also showed scattered chromogranin or synaptophysin positive 
cells (Fig 6G-I). NE-low molecular type tumors with isolated-cell histology similarly had 
neuroendocrine expressing cells. In one such tumor, two differently staining neuroendocrine 
elements corresponded to two distinct H&E appearances: one with intracellular mucin and 
signet ring cell appearance and the other with enlarged vesicular nuclei, prominent nucleoli, 
and eosinophilic cytoplasm (Fig 6J-O). In retrospect, these atypical nuclear features might 
be consistent with large cell neuroendocrine carcinoma (see Discussion).
Agreement between neuroendocrine differentiation by morphology and 
immunohistochemistry is imperfect
Several tumors with features of neuroendocrine differentiation assessed by H&E showed at 
least focal synaptophysin and/or chromogranin staining (Fig 4). These tumors often had 
multiple morphologies within the same tumor evident even in small biopsy specimens. For 
example, one synaptophysin-positive case showed areas of tumor forming neuroendocrine 
rosettes and areas of solid nests (Fig 4A-C). The nuclear features were high-grade in both 
areas with hyperchromasia and nuclear molding. Several other cases had clearly distinct 
gland-forming/tubular and nested neuroendocrine components (Fig 4D). A small cell 
carcinoma that was chromogranin-positive had scattered signet ring cells (Fig 4E-F).
However, the initial morphologic assessment of neuroendocrine features did not always 
correlate with positive immunohistochemistry for synaptophysin and chromogranin. At least 
one case considered to be a high-grade neuroendocrine carcinoma by H&E did not show any 
synaptophysin or chromogranin reactivity (Fig 7A-B). This tumor had nested architecture 
and two cytologically distinct cell populations, one with finely clumped, salt-and-pepper 
chromatin and more abundant cytoplasm, and the other with nuclear hyperchromasia, 
increased nuclear/cytoplasmic ratio, and nuclear molding. Conversely, an NE-low molecular 
subtype tumor that was initially not noted to have neuroendocrine features on H&E showed 
synaptophysin positivity. This tumor was classified as a group 1 isolated-cell carcinoma 
with pleomorphic signet ring cells although with unusually little stromal fibrosis (Fig 7C). 
On re-examination there were minor areas of trabecular/nested growth composed of 
eosinophilic non-signet ring cells with hyperchromatic nuclei, indistinct cell borders, and 
nuclear molding—features of high grade neuroendocrine carcinoma (Fig 7D). Lack of 
fibrosis and packed appearance of both signet ring cells and eosinophilic cells can also favor 
classification as solid carcinoma. In our experience, however, solid carcinomas without 
neuroendocrine features have a different appearance with round cell shapes, well-defined 
cellular borders, absent nuclear molding, and sheet-like rather than nested growth. Fig 7E 
shows one such tumor of the NE-low molecular subtype classified as solid (group 4). This 
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tumor showed no neuroendocrine differentiation by chromogranin or synaptophysin 
immunohistochemistry.
Discussion
In this study, RNA expression arrays were applied to profile and cluster gastric cancer 
tissues, which yielded three molecular types of cancer. These three molecular types were 
distinguished from one another based primarily on EBV status and by the degree of 
expression of neuroendocrine RNAs. Furthermore, these molecular types correlated in part 
with histologic features and with histochemical test results for EBV infection and for 
neuroendocrine differentiation. The EBV-positive molecular type cancers uniformly 
expressed EBER in the malignant cells by in situ hybridization. We previously showed that 
these infected cancers expressed multiple EBV genes as well as a subset of human genes 
involved in inflammatory response (TNFSF9, TRAF1, CXCL11, IFITM1 and FCRL3)45. 
Overexpression of the B cell markers MS4A1 (CD20) and FCER2 (CD23), and the 
suppressor T cell marker CD8 are consistent with the chronic inflammatory cell infiltrate in 
these tumors and their frequent morphologic diagnosis as “gastric carcinoma with lymphoid 
stroma”. The correlation between the abundant tumor-infiltrating lymphocytes and the 
molecular evidence of inflammatory response lends validity to the molecular profiling 
system used in this study.
EBV-positive cancers in this study tended to have solid morphology with minimal fibrosis, 
features noted by others as well19,51. This morphologic type is distinguished by the Carneiro 
gastric cancer classification but not by the Lauren classification. EBV-positive cancers also 
had more chronic inflammation in keeping with lymphoid stroma rather than fibrotic stroma. 
None of the EBV-positive cancers were signet ring cell type, although more cases must be 
studies to evaluate whether this findings is significant.
A significant finding in the EBV-positive cancers was the lack of neuroendocrine 
differentiation as evaluated by H&E histology, immunohistochemistry, and RNA 
expression. Molecular profiling divided the non-infected cancers in this study into two 
groups that differed from each other in the expression of three RNAs known to be associated 
with neuroendocrine cell differentiation in the gut, CGHA, GAST, and REG453,54,55. 
However, we did not find a significant correlation between RNA expression and 
neuroendocrine appearance on H&E. There was also no correlation between chromogranin 
protein positivity assessed by immunohistochemistry and chromogranin RNA expression. 
Discordance between chromogranin protein and RNA expression has been described in 
pulmonary small cell carcinomas56,57,58. Immunoreactivity for chromogranin is associated 
with the presence of neurosecretory granules in tumor cells, and many high-grade 
neuroendocrine carcinomas have absent or aberrant production of such granules. Among 
primary pulmonary small cell carcinomas, immunopositivity for chromogranin is generally 
only around 80%59 and has been reported as low as 23%60. Absent or focal chromogranin 
staining in gastric neuroendocrine carcinomas is also a known phenomenon with reported 
chromogranin positivity of 40%61. The lack of correlation between neuroendocrine RNA 
expression level and neuroendocrine morphology in this study may be due to 1) the small 
number of tumors with neuroendocrine morphology, 2) poor reproducibility of 
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neuroendocrine carcinoma morphologic diagnosis, 3) expression of neuroendocrine RNAs 
in non-malignant cells, or 4) biopsy sampling may not be representative of the entire tumor. 
We conclude that while neuroendocrine RNAs seem to be major drivers of molecular 
subtype in this study, it was not possible to use H&E nor standard immunostain evidence of 
neuroendocrine differentiation to predict molecular subtype.
In two-way analysis, NE-high and NE-low molecular types differed not only in 
neuroendocrine related transcripts but also in the expression levels of several other genes 
involved in intercellular signaling and adhesion as well as inflammation and metabolism. It 
should be noted that only 73 human RNAs were profiled, and thus there is limited ability to 
examine pertinent biochemical pathways in these tumors.
Recent progress towards targeted therapy for gastric cancer is refining the way that cancer is 
classified. Already implemented in routine patient care are tests for ERBB2(HER2) protein 
expression or gene amplification as a means to predict therapeutic efficacy of trastuzumab. 
In our study, ERBB2 RNA was expressed in some tumors but it was not differentially 
expressed among the three molecular types that we delineated45. Multiple investigators are 
pursuing strategies for virus-targeted therapy in the subset of cancers that are EBV-
infected62,63,64,65. Efforts focused on molecular and histochemical assays will add value to 
the histopathologic classification of gastric cancer given the inter- and intra-tumoral 
heterogeneity that confounds histologic evaluation.
Our findings highlight the difficulty in applying neuroendocrine carcinoma designation. 
Some tumors assessed as having neuroendocrine morphology by H&E were negative for 
chromogranin or synaptophysin immunohistochemistry. Conversely, some tumors not 
suspected to have neuroendocrine differentiation showed neuroendocrine marker positivity 
by immunohistochemistry. Multiple studies have found that neuroendocrine differentiation 
is under-recognized by morphology alone, and ancillary methods often reveal evidence of it 
in various tumor types39,47,55,66. Large cell neuroendocrine carcinoma is especially difficult 
to distinguish from poorly differentiated adenocarcinoma because of overlapping cytologic 
features and growth patterns, and even accumulation of intracellular mucin is permissible in 
large cell neuroendocrine carcinoma33,34,35. In our study we observed inter- and intra-
tumoral heterogeneity in tumors with neuroendocrine morphologic features as well.
One important question is: does neuroendocrine differentiation in gastric cancer have 
clinical implications? It seems clear that tumors fulfilling the diagnostic criteria for small 
cell carcinoma are a distinct group of biologically aggressive malignancies67. 
Prognostication becomes more difficult when the high grade neuroendocrine component 
constitutes only part of the tumor. One study set a threshold for tumor designation as large 
cell neuroendocrine carcinoma if the neuroendocrine component was >50% of the tumor by 
chromogranin immunostain33. In that study, adenocarcinomas with 20 to 50% 
chromogranin-positive large cell neuroendocrine component showed reduced survival 
compared to adenocarcinoma with no neuroendocrine component. There have been 
conflicting reports of a worse37,39 or better41,68 prognosis associated with any focal 
neuroendocrine differentiation by immunohistochemistry. Given the uncertainty of the 
morphologic criteria and the variability of protein immunohistochemistry, it seems logical to 
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ask if an RNA-based molecular test may provide a more objective measure of 
neuroendocrine differentiation. Further studies are necessary to test if an RNA threshold is 
clinically significant, and to compare the performance of RNA-based tests to protein 
immunohistochemistry. It is likely that tumors with a clinically significant level of 
neuroendocrine differentiation would be defined not by a single RNA but by a panel of 
several RNA markers such as the ones used in this study. An important limitation of this 
study is the lack of outcome data to determine if the three molecular subtypes correspond to 
gastric cancer subsets with clinically significant differences in disease progression or 
response to therapy.
In conclusion, our study shows molecular evidence of neuroendocrine differentiation in over 
a third of gastric adenocarcinomas. However, EBV-infected tumors completely lack 
neuroendocrine differentiation either in their molecular profile or by morphology. EBV-
infected are predominantly solid morphologic type which is distinguished by the Carneiro 
histologic classification but not the Lauren classification. Our study also confirms that 
molecular profiling has promise as a robust tool, applicable in small fixed biopsies, to add 
value in classifying gastric cancer.
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Figure 1. Differential expression of neuroendocrine (NE) RNAs by molecular subtype of gastric 
cancer
CHGA (chromogranin), GAST (gastrin), and REG4 are expressed more highly in NE-high 
molecular type cancers compared to EBV-positive or NE-low molecular types.
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Figure 2. Morphologic range of EBV-positive gastric adenocarcinomas
(A) Gastric cancer with lymphoid stroma has undifferentiated epithelial nests surrounded by 
a lymphoplasmacytic infiltrate with lack of stromal desmoplasia; (B) EBER RNA is 
expressed in the malignant epithelial cells. (C) Solid carcinoma is a sheet-like proliferation 
of malignant epithelial cells with deep eosinophilic cytoplasm and virtually no intervening 
fibrous or lymphoid stroma; (D) EBER RNA is expressed in the malignant epithelial cells. 
(E) Solid carcinoma with areas of gland formation in a lymphoid stroma without significant 
fibrosis; (F) EBER RNA is expressed in the malignant epithelial cells.
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Figure 3. Distribution of the four histologic groups (relative proportions) among the three 
molecular types
EBV-positive carcinomas are predominantly group 4 solid while very few of the NE-high 
molecular type tumors are classified in that group. Instead, the NE-high molecular type is 
enriched for tumors having group 1 isolated-cell histology while none of the EBV-positive 
cancers are classified as isolated-cell morphology (p<0.05, Chi-square test).
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Figure 4. Morphologic heterogeneity of carcinomas with neuroendocrine features
A carcinoma with high-grade neuroendocrine nuclear features such as hyperchromasia and 
nuclear molding has areas of rosettes (A) and solid nests (B) and shows focal synaptophysin 
positivity in both areas (C, only nested area is shown). (D) A neuroendocrine tumor with 
two intermingled morphologies, visible as gland-forming and solid areas, demonstrates 
cellular monotony, unapparent cellular borders, and evenly dispersed chromatin in both 
morphologic components but more ample eosinophilic cytoplasm in the solid nests. (E-F) 
Small cell carcinoma with nuclear molding and crush artifact has rare cells with signet ring 
morphology (E, arrow in inset) and is focally positive for chromogranin (F).
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Figure 5. Differential expression of CHGA and PLUNC by Carneiro histologic groupings
CHGA is expressed at higher levels in histologic groups 1 and 3 while PLUNC is expressed 
at a higher level in histologic group 4.
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Figure 6. Neuroendocrine differentiation is observed in diffuse cancers of the NE-high and NE-
low molecular types but not in the EBV-positive type
(A) Solid carcinoma of EBV-positive molecular type is negative for chromogranin (B) and 
synaptophysin (C) with positive internal control in the neuroendocrine cells of residual non-
neoplastic gastric pits (insets in B and C). (D) A carcinoma of NE-high molecular type and 
infiltrating isolated-cell histology has scattered individual malignant cells expressing 
chromogranin (E) and synaptophysin (arrows, F). (G) Similarly, a signet ring cell carcinoma 
of NE-high molecular type has chromogranin (H) and synaptophysin expressing cells 
(arrows, I). Synaptophysin also highlights small nerve twigs within the abundant fibrous 
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stroma (arrowheads, F and I). (J-O) An infiltrative carcinoma of NE-low molecular type has 
focal areas of small nests and short cords of cells with enlarged vesicular nuclei, prominent 
nucleoli, and eosinophilic cytoplasm (J), other focal areas in which the nests of eosinophilic 
cells have admixed signet ring cells (K), but predominantly the tumor consists of 
eosinophilic and signet ring cells infiltrating singly (M). All three of these tumor 
morphologies are embedded in dense fibrous stroma. Nested areas have individual 
chromogranin positive cells within the nests (L). The singly infiltrating eosinophilic cells are 
chromogranin positive and synaptophysin negative while the signet ring cells have the 
reverse pattern—chromogranin negative and synaptophysin positive (N,O).
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Figure 7. Agreement between neuroendocrine differentiation by morphology and 
immunohistochemistry is imperfect
(A-B) A tumor with two distinct neuroendocrine cytologic patterns on H&E, salt-and-pepper 
chromatin (A, upper right) and hyperchromasia and nuclear molding (A, lower left) is 
negative for synaptophysin (B, arrows at tumor cells with crush artifact) with positive 
internal control synaptophysin staining in the stromal nerve (B, arrowhead). The tumor cells 
are also negative for chromogranin protein (not shown). (C-D) An NE-high molecular 
subtype carcinoma has spatially separate zones of pleomorphic signet ring cells (C) and 
trabecular/solid nests of non-signet ring cells with high grade neuroendocrine morphology 
(D). In both zones the malignant cells express synaptophysin (insets in G and H). (E) A 
carcinoma of NE- low molecular type and solid histology has well-defined cellular borders, 
prominent nucleoli, absent nuclear molding, and sheet-like growth, and is negative for 
chromogranin (inset) and synaptophysin (not shown).
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Table 1
RNAs significantly differentially expressed in NE-high and NE-low molecular types of gastric 
adenocarcinoma
a
Gene symbol Colloquial name Description or function Direction of difference
b
SULF1 Cell signaling, sulfatase ↓
CHGA chromogranin Neuroendocrine cell, gastrin signaling ↑
SPP1 Osteogenesis, secreted phosphoprotein ↓
FSCN1 Cell morphology and motility ↓
TNFSF9 Antigen processing, TNF ligand cytokine ↓
INBA inhibin Hormonal regulation and cell growth ↓
FCGR2B Phagocytosis and antibody production ↓
PTGS2 COX2 Prostaglandin and gastrin signaling ↓
GAST gastrin Neuroendocrine cell, stimulation of acid secretion ↑
ICAM1 Cell adhesion ↓
SLC2A1 Glut 1 Glucose transporter ↓
CD4 Helper T cells, MHC class II antigen processing ↓
CD70 TNF ligand, T and NK cell activation ↓
DKK4 Embryonic development ↓
SERPINH1 Collagen synthesis, peptidase inhibitor, heat shock ↓
TRAF1 TNF receptor ↓
CXCL1 Immune development and homeostasis ↓
IGLL1 CD179b B cell growth ↓
SPARC osteonectin Protects from apoptosis, docetaxel response ↓
REG4 Neuroendocrine cell, regenerative islet-derived family ↑
COL1A1 Type I collagen component ↓
EBER1 Non-coding viral RNA
GPR183 EBI2 G-protein coupled receptor, EBV-induced ↓
EBER2 Non-coding viral RNA
COL1A2 Type I collagen component ↓
BLLF1 Viral RNA, entry via CD21 receptor
HIF1A Systemic response to hypoxia ↓
TYMS Thymidilate synthase, 5FU response ↓
THY1 Control of inflammatory cell recruitment ↓
BCL2L11 BIM Activator of apoptosis, BCL2-like ↓
COL3A1 Type III collagen component ↓
a
FDR adjusted P values are <0.05 for all RNAs listed in the table; RNAs are ranked with most significant P values near the top
b
Up arrows indicate RNAs expressed at a higher level in NE-high compared to NE-low subtype, and down arrows indicated RNAs expressed at a 
lower level in NE-high compared to NE-low subtype.
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Table 2
Histopathologic features in three molecular subtypes of gastric adenocarcinoma
Molecular Subtype
Histologic feature # of 
cases, 
n=103







    Mild 42 0 18 24
    Moderate 45 5 14 26
    Severe 16 9 2 5
Stromal fibrosis 0.0008 0.0001
    Mild 29 11 5 13
    Moderate 47 2 15 30
    Severe 12 0 6 6
    Indeterminate




    Intestinal 30 3 11 16
    Diffuse 36 6 15 15
    Unclassified







    1: isolated-cell 24 0 14 10
    2: gland-forming 23 3 7 13
    3: mixed 18 1 7 10
    4: solid 17 8 1 8
    Unclassified
a
,
b 21 2 5 14
Neuroendocrine morphology 0.25 0.2
    Yes 14 0 4 10
    No 89 14 30 45
Gastric cancer with lymphoid 
stroma
<0.0001 <0.0001
    Yes 8 7 0 1
    No 95 7 34 54
Signet ring cell carcinoma 0.002 0.12
    Yes 15 0 11 4
    No 88 14 23 51
a
Due to limited nature of biopsy material
b
Unclassified cases include tumors with neuroendocrine morphology
c
Based on Carneiro histopathologic classification
d
Statistical analysis of all three molecular subtypes
e
Statistical analysis of the EBV-positive and EBV-negative (combined NE-high and NE-low) cancers
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f
Determined by Chi-square test; all other P values determined by two-tailed Fisher's exact test
Appl Immunohistochem Mol Morphol. Author manuscript; available in PMC 2016 October 01.
